Patents Assigned to Dignity Health
-
Patent number: 9636162Abstract: System and method for automatically bending a surgical rod are provided. The system includes a linear movement device configured to axially feed the surgical rod, a rotational movement device configured to rotate the surgical rod as it is axially fed, and a bending device including a roller to impose bending forces against the rod. The rod is free from contact with the bending device after it is axially fed past the roller.Type: GrantFiled: December 5, 2012Date of Patent: May 2, 2017Assignee: Dignity HealthInventors: Neil R. Crawford, Nicholas Theodore, Philip M. Reyes, Anna G. U. S. Newcomb, Seungwon Baek
-
Patent number: 9637798Abstract: The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG.Type: GrantFiled: May 21, 2014Date of Patent: May 2, 2017Assignees: Dignity Health, The Translational Genomics Research InstituteInventors: Shwetal V. Mehta, Michael E. Berens, Harshil Dineshkumar Dhruv
-
Publication number: 20170089925Abstract: The present invention relates to methods of diagnosing samples as well as various microfluidic, microcentrifuge and microfilter devices. In one embodiment, the present invention provides a method of diagnosing neurodegenerative diseases using mitochondrial and/or platelet samples. In another embodiment, the present invention provides a microfluidic device that selectively captures and analyzes a desired amount of target biological particle.Type: ApplicationFiled: September 1, 2016Publication date: March 30, 2017Applicant: Dignity HealthInventor: Jonathan E. Valla
-
Patent number: 9572972Abstract: Systems and methods for applying stimulating current to a patient for treating insufficient uterine contractions are provided. The system includes stimulation electrodes of a balloon electrode array device, a ring electrode array device, an electrode probe device, or a mesh electrode array device. Some aspects of the invention also provide a connector and cable device for coupling the stimulation electrodes to electronics for generating and providing the stimulating current to the stimulation electrodes.Type: GrantFiled: January 29, 2015Date of Patent: February 21, 2017Assignee: Dignity HealthInventors: Robert E. Garfield, Harvey Carp, William L. Maner
-
Patent number: 9566273Abstract: The present invention relates to methods of treating and/or ameliorating the severity of inflammation and autoimmunity in the central nervous system (CNS). In one embodiment, the present invention provides a method of treating multiple sclerosis by administering a therapeutically effective dosage of nicotine, or a pharmaceutical equivalent, analog, derivative, or salt thereof.Type: GrantFiled: August 4, 2014Date of Patent: February 14, 2017Assignee: Dignity HealthInventors: Fu-Dong Shi, Ronald J. Lukas, Timothy Vollmer
-
Patent number: 9533151Abstract: Disclosed herein are methods, systems, and apparatus for treating a medical condition in a patient using an implantable medical device by applying an electrical signal characterized by having a number of pulses per microburst, an interpulse interval, a microburst duration, and an interburst period to a portion of a cranial nerve of said patient, wherein at least one of the number of pulses per microburst, the interpulse interval, the microburst duration, or the interburst period is selected to enhance cranial nerve evoked potentials.Type: GrantFiled: January 10, 2014Date of Patent: January 3, 2017Assignee: DIGNITY HEALTHInventor: Arthur D. Craig
-
Patent number: 9527823Abstract: The invention provides hydroxybupropion analogs capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and/or may selectively bind to one or more nicotinic acetylcholine receptor subtypes. Such compounds may be used to treat conditions that are responsive to modification of monoamine levels and/or antagonism of nicotinic acetylcholine receptors, including drug dependency, depression, and obesity.Type: GrantFiled: November 10, 2014Date of Patent: December 27, 2016Assignees: Research Triangle Institute, Dignity Health, Virginia Commonwealth UniversityInventors: Frank Ivy Carroll, Bruce E. Blough, Hernan A. Navarro, S. Wayne Mascarella, Ana Zamfira Muresan, M. Imad Damaj, Ronald J. Lukas
-
Publication number: 20160356787Abstract: Described herein are methods and compositions for the diagnosis, prognosis, selection of treatment and treatment of cancer, and particularly, of lung cancer such as non-small cell lung cancer. Embodiments of the present invention involve the detection of LKB1 levels and sensitivity to endoplasmic reticulum (ER) stress. Treatment can be made through the administration of ER stress activators.Type: ApplicationFiled: February 18, 2015Publication date: December 8, 2016Applicant: Dignity HealthInventor: Landon J. Inge
-
Publication number: 20160305962Abstract: Described herein are methods, systems and compositions for the diagnosis, prognosis and treatment of dementia and Alzheimers disease. Also described are methods, systems and compositions to distinguish between Alzheimers disease and Parkinsons disease. In various embodiments levels of PACAP and/or SIRT3 are analyzed for the diagnosis, prognosis and treatment of dementia and Alzheimers disease.Type: ApplicationFiled: December 23, 2014Publication date: October 20, 2016Applicant: Dignity HealthInventors: Jiong Shi, Peng Cheng Han
-
Patent number: 9463458Abstract: The present invention relates to methods of diagnosing samples as well as various microfluidic, microcentrifuge and microfilter devices. In one embodiment, the present invention provides a method of diagnosing neurodegenerative diseases using mitochondrial and/or platelet samples. In another embodiment, the present invention provides a microfluidic device that selectively captures and analyzes a desired amount of target biological particle.Type: GrantFiled: March 2, 2010Date of Patent: October 11, 2016Assignee: Dignity HealthInventor: Jonathan E. Valla
-
Publication number: 20160250355Abstract: The present disclosure is directed to methods and a diagnostic kit for producing pericyte information from a subject for identifying and/or treating a subject condition. In one aspect, a method for identifying a subject condition is provided. The method includes administering intravenously to a subject an effective amount of a solution comprising fluorescent markers to selectively label a plurality of pericytes in the subject's body. The method also includes acquiring fluorescence signals originating from labeled pericytes to produce pericyte information associated with tissues of the subject's body. The method further includes generating a report identifying a subject condition using the pericyte information. In some aspects, a treatment may be adapted using the identified subject condition.Type: ApplicationFiled: October 16, 2014Publication date: September 1, 2016Applicant: DIGNITY HEALTHInventor: Stephen L. Macknik
-
Publication number: 20160238618Abstract: The invention relates to diagnosis, prognosis and treatment of neurological diseases. In one embodiment, the present invention provides methods and kits that diagnose whether a subject has a neurological disease or susceptibility to a neurological disease by evaluating nuclear stress body (NSB) levels. Further described are methods and kits that prognose a neurological disease in a subject by monitoring changes in NSB levels. Also described are methods and kits that treat neurological diseases by administering one or more inhibitors of NSB signaling to a patient, as well as compositions containing one or more NSB signaling inhibitors. Medical conditions suitable with various embodiments of the invention include but are not limited to ALS, FTLD, dementia and AD.Type: ApplicationFiled: November 7, 2014Publication date: August 18, 2016Applicant: Dignity HealthInventors: Robert Bowser, Mahlon Collins
-
Publication number: 20160235322Abstract: An improved apparatus and method of using an EEG net to obtain electroencephalographic measurements from a patient in an emergent or urgent care setting. The net is comprised of a headpiece with a plurality of straps and recording ports formed therein. A recording head of an electrode is associated with each recording port and is pre-incorporated into the net. Transmitting wires are associated with each electrode head and have common terminated points. The terminus of each wire is hard wired into a connecting device that can be directly mated to a receiving console or remotely transmit wirelessly the electrode signals.Type: ApplicationFiled: April 27, 2016Publication date: August 18, 2016Applicant: Dignity HealthInventor: Brian Alkire
-
Publication number: 20160175325Abstract: As disclosed herein, novel compositions including steroid hormones, such as trimegestone (TMG) and progesterone (P4), provide treatments for term and preterm labor with significant effects on the delay of delivery. Delay and block of delivery occurs when both P4 and TMG are administered late in gestation in pregnant rat and guinea pig animal models. TMG exhibits remarkable drug efficacy, achieving the same inhibition as P4, but at much lower doses. These hereto unknown effects of TMG on the processes of cervical ripening and uterine contraction provide a novel approach for extending pregnancy term, including reducing a likelihood of preterm and/or term labor, along with improved methods of administration. Other diseases and/or conditions may be treated with TMG, such as dysmenorrhea or luteal insufficiency for sustaining pregnancy.Type: ApplicationFiled: January 22, 2016Publication date: June 23, 2016Applicant: DIGNITY HEALTHInventors: Robert E. Garfield, Shao-Qing Shi, Leili Shi
-
Patent number: 9351816Abstract: An electric toothbrush for use by an operator and capable of being connected to a suction device. The electric toothbrush includes a head with a plurality of bristles, at least one irrigation port, and at least one suction port, and an injection port in fluid communication with the at least one irrigation port. The electric toothbrush also includes a handle with a ventilation port in fluid communication with the at least one suction port, a user interface, and a controller. The ventilation port permits suction from the suction device to the at least one suction port and the controller is configured to actuate at least one of rotation, oscillation, and vibration of the bristles for a preset time period in response to a predetermined feedback from the operator through the user interface.Type: GrantFiled: April 1, 2013Date of Patent: May 31, 2016Assignee: Dignity HealthInventors: Virginia Prendergast, Cynthia Kleiman
-
Patent number: 9345418Abstract: An electroencephalography system is provided. The electroencephalography system includes a support structure that covers at least predetermined areas on a patient's head, a plurality of electrodes mounted on the support structure so that, the electrodes are distributed around the patient's head and measure usable electrical signals that are representative of electrical activity or activity in a patient's head, a plurality of transmitting wires incorporated into the support structure, a multi-pin connector having an output and an input, each of the plurality of transmitting wires directly connected between a respective one of each of the plurality of electrodes and a corresponding pin of the multi-pin connector so that, electrical signals are sent to the output of the connector and a first transmitter that is capable of being operatively coupled to the output of the connector.Type: GrantFiled: March 27, 2008Date of Patent: May 24, 2016Assignee: Dignity HealthInventor: Brian Alkire
-
Publication number: 20160102360Abstract: The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG.Type: ApplicationFiled: May 21, 2014Publication date: April 14, 2016Applicants: The Translational Genomics Research Institute, Dignity HealthInventors: Shwetal V. Mehta, Michael E. Berens, Harshil Dineshkumar Dhruv
-
Patent number: 9301679Abstract: A method and apparatus including identifying a plurality of at least partially repetitive eye movements of a person, the eye movements defined by a first predominantly horizontal saccadic movement that moves the eye away from a fixation target followed by a corrective saccadic movement towards the target shortly thereafter, measuring a vertical component associated with the plurality of eye movements and comparing the vertical component with a predetermined threshold value.Type: GrantFiled: March 20, 2014Date of Patent: April 5, 2016Assignee: Dignity HealthInventors: Susana N. Martinez-Conde, Stephen L. Macknik, Xoana Troncoso, Jorge Otero-Millan
-
Patent number: 9289599Abstract: An implanted electrical signal generator delivers a novel exogenous electrical signal to a vagus nerve of a patient. The vagus nerve conducts action potentials originating in the heart and lungs to various structures of the brain, thereby eliciting a vagal evoked potential in those structures. The exogenous electrical signal simulates and/or augments the endogenous afferent activity originating from the heart and/or lungs of the patient, thereby enhancing the vagal evoked potential in the various structures of the brain. The exogenous electrical signal includes a series of electrical pulses organized or patterned into a series of microbursts including 2 to 20 pulses each. No pulses are sent between the microbursts. Each of the microbursts may be synchronized with the QRS wave portion of an ECG. The enhanced vagal evoked potential in the various structures of the brain may be used to treat various medical conditions including epilepsy and depression.Type: GrantFiled: April 3, 2012Date of Patent: March 22, 2016Assignee: DIGNITY HEALTHInventor: Arthur D. Craig
-
Patent number: 9271991Abstract: As disclosed herein, novel compositions including steroid hormones, such as trimegestone (TMG) and progesterone (P4), provide treatments for term and preterm labor with significant effects on the delay of delivery. Delay and block of delivery occurs when both P4 and TMG are administered late in gestation in pregnant rat and guinea pig animal models. TMG exhibits remarkable drug efficacy, achieving the same inhibition as P4, but at much lower doses. These hereto unknown effects of TMG on the processes of cervical ripening and uterine contraction provide a novel approach for extending pregnancy term, including reducing a likelihood of preterm and/or term labor, along with improved methods of administration. Other diseases and/or conditions may be treated with TMG, such as dysmenorrhea or luteal insufficiency for sustaining pregnancy.Type: GrantFiled: October 27, 2011Date of Patent: March 1, 2016Assignee: Dignity HealthInventors: Robert E. Garfield, Shao-Qing Shi, Leili Shi